← Crinetics Pharmaceuticals overview

Crinetics Pharmaceuticals vs Gilead Sciences: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Crinetics Pharmaceuticals Inc (CRNX)

Q3 2026
▲2▼1

Vertex's $10B buyout of Crinetics caps the stock near $85

  • Vertex agrees to buy Crinetics for $85/share cash Vertex will acquire Crinetics for about $10 billion, or $85 per share in cash — roughly double the prior price. Both boards unanimously approved the deal, expected to close in the third quarter of 2026.

    This is the single biggest event of the period and the main reason the stock moved.

  • Deal validates key drugs and strong sales The buyout confirms the value of Palsonify, the first once-daily oral acromegaly drug, and atumelnant for congenital adrenal hyperplasia. Palsonify sales jumped to $24 million in Q2 from $10.3 million in Q1, with 385 prescribers.

    It explains why Vertex paid a premium and supports the offer price.

  • Legal probe into board's deal process Ademi LLP is investigating whether Crinetics' board breached its duties by accepting the deal, pointing to a large penalty for a rival bid and insider payouts. This creates uncertainty about whether the $85 payout will go through as planned.

    It is the main risk that could derail or delay the deal, a real counterweight.

  • Upside capped near offer price With the deal expected to close, the stock is likely to trade near $85 unless a rival bid emerges. That limits further gains for current shareholders, even as the buyout locks in a big premium.

    It sets expectations for the stock's range after the deal news.

July 2026
▲2▼1

Vertex's $10B buyout of Crinetics caps the stock near $85

  • Vertex agrees to buy Crinetics for $85/share cash Vertex will acquire Crinetics for about $10 billion, or $85 per share in cash — roughly double the prior price. Both boards unanimously approved the deal, expected to close in the third quarter of 2026.

    This is the single biggest event of the period and the main reason the stock moved.

  • Deal validates key drugs and strong sales The buyout confirms the value of Palsonify, the first once-daily oral acromegaly drug, and atumelnant for congenital adrenal hyperplasia. Palsonify sales jumped to $24 million in Q2 from $10.3 million in Q1, with 385 prescribers.

    It explains why Vertex paid a premium and supports the offer price.

  • Legal probe into board's deal process Ademi LLP is investigating whether Crinetics' board breached its duties by accepting the deal, pointing to a large penalty for a rival bid and insider payouts. This creates uncertainty about whether the $85 payout will go through as planned.

    It is the main risk that could derail or delay the deal, a real counterweight.

  • Upside capped near offer price With the deal expected to close, the stock is likely to trade near $85 unless a rival bid emerges. That limits further gains for current shareholders, even as the buyout locks in a big premium.

    It sets expectations for the stock's range after the deal news.

Latest
▲2▼1

Vertex's $10B Crinetics buyout advances, with a legal probe and strong drug sales

  • Law firm probes deal fairness Ademi LLP is investigating whether Crinetics' board breached its duties by accepting the Vertex deal, noting a big penalty if Crinetics takes a rival bid and large insider payouts. This could delay or complicate the deal, a risk to the $85 payout.

    This is the main new counterweight that could threaten deal completion.

  • PALSONIFY sales jump to $24 million Crinetics reported second-quarter 2026 PALSONIFY revenue of $24.0 million, up from $10.3 million in the first quarter, with 385 prescribers and over 70% of patients on reimbursed therapy. Strong launch momentum supports the value Vertex is paying.

    New sales data shows the commercial launch is ahead of prior levels, reinforcing deal value.

  • Biotech M&A wave lifts sector Biotech IPOs are up 55% this year, far outpacing the broader market, helped by big pharma takeovers including Vertex-Crinetics. This read-through supports biotech stocks broadly, but for CRNX the main effect is already captured in the agreed $85 cash price.

    Shows the sector backdrop that supports CRNX's valuation, though its own upside is capped by the deal.

▲4

Vertex's $10B buyout locks in a huge premium for Crinetics

  • Vertex to acquire Crinetics for $10B Vertex Pharmaceuticals agreed to buy Crinetics for $85 per share in cash, about $10 billion, a roughly 100% premium. The deal, unanimously approved by both boards, is expected to close in the third quarter of 2026. This sets a firm floor near the offer price and is the main reason CRNX jumped.

    The buyout is the single event that now determines CRNX's price.

  • Buyout validates Palsonify and atumelnant Vertex gains Palsonify, the first once-daily oral acromegaly drug, and atumelnant, a late-stage oral treatment for congenital adrenal hyperplasia. Vertex expects over $5 billion in combined peak yearly sales. This confirms the commercial value of Crinetics' pipeline and explains why Vertex paid such a high price.

    It shows the strategic reason behind the premium and supports the deal's credibility.

  • Strong Phase 2 atumelnant data New Phase 2 results showed atumelnant cut morning androstenedione by 67% on average at week 12 and let 7 of 8 patients reach normal steroid doses, with no serious side effects. Updated two-year paltusotine data also held up. These results made Crinetics a more attractive takeover target.

    The data directly boosted Crinetics' appeal and helped justify the buyout price.

  • Buyout sparks sector takeover interest After the Vertex-Crinetics deal, investors turned to other possible targets like Viking Therapeutics, betting large pharma will keep buying. This read-through supports biotech stocks broadly, but for CRNX the main effect is already captured in the agreed $85 cash price, so further upside is limited unless a rival bid appears.

    It shows the wider market reaction, while noting CRNX's price is now tied to the deal terms.

Gilead Sciences Inc (GILD)

Q3 2026
▲3▼1

Gilead Q3: HIV strength, new launches, but big writedown weighs

  • Q2 revenue up 10%, HIV sales up 12%, guidance raised Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12%, and the company raised its full-year guidance. This shows the core business is growing and management is more confident about the future.

    This is the main positive force behind the stock this quarter, showing stronger sales and a brighter outlook.

  • Four planned launches and new approvals broaden business beyond HIV Gilead is preparing four new product launches and won approvals for Bixlenvo and a Trodelvy/Keytruda combination. This diversification reduces reliance on HIV and opens new revenue streams, which supports the stock.

    It shows concrete progress in expanding beyond HIV, a key part of the bull case this quarter.

  • Legal win protects Biktarvy; PAHO deal expands lenacapavir access Gilead won a legal case protecting its key HIV drug Biktarvy from generic competition, and signed a deal with PAHO to expand access to lenacapavir. These reduce competitive threats and open new markets, helping the stock.

    These events remove a major risk and add a growth avenue, both new this quarter.

  • $11.2B acquired IPR&D charge causes $8.45 GAAP loss Gilead reported a GAAP loss of $8.45 per share due to an $11.2 billion charge for acquired in-process research and development. This accounting charge weighed on reported earnings, though it doesn't reflect cash flow or ongoing operations.

    It is the main negative factor this quarter, explaining why reported earnings looked bad despite strong sales.

September 2026
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

Latest
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

August 2026
▲3▼1

Gilead Q2 beat, HIV strength, new drug approvals, but accounting loss

  • Q2 earnings beat and raised guidance Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12% and PrEP topping $1 billion. The company raised its full-year HIV growth outlook to 9–10%, signaling confidence.

    This is the main positive force behind the stock, showing strong operational performance.

  • New HIV and cancer drug approvals The FDA approved Bixlenvo, a new single-tablet HIV regimen, and the EU expanded Trodelvy plus Keytruda for first-line triple-negative breast cancer. These expand Gilead's product lineup and market reach.

    These approvals are new revenue drivers and reinforce Gilead's competitive position.

  • Large accounting loss from acquisitions Gilead reported a GAAP loss of $8.45 per share due to $11.2 billion in acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines. This is an accounting charge, not an operational loss, but it weighed on reported earnings.

    This explains the headline loss and why it may not reflect underlying business health.

  • Analyst confidence and pipeline progress BofA reiterated a Buy rating with a $162 target, and Gilead advanced its pipeline in oncology and a once-weekly oral HIV regimen. However, these pipeline gains are early and not yet near-term revenue.

    Analyst support and pipeline advances support the stock, though with limited immediate impact.

▲4

Gilead's HIV engine accelerates with new drug approvals and raised guidance

  • HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.

    This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.

  • FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.

    A new product approval expands the addressable market and future revenue, directly lifting growth prospects.

  • European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.

    A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.

  • Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.

    New pipeline additions signal longer-term growth potential, which can support a higher valuation.

▲3▼1

Gilead's Q2 beat and raised guidance show HIV strength, but acquisition charges hit reported EPS

  • Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.

    This is the period's central event and directly explains the positive fundamental momentum behind GILD.

  • PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.

    It highlights a key new growth driver that is boosting investor confidence and future sales.

  • Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.

    It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.

  • Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.

    It shows external validation and pipeline progress that support the stock's longer-term growth story.

July 2026
▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

Q2 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

June 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

© 2026 MarketIVWhy